Hemostemix Inc. (CVE:HEM – Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 112196 shares traded. The stock had previously closed at C$0.06.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.49 and a debt-to-equity ratio of -72.45. The stock has a market capitalization of C$10.88 million, a PE ratio of -1.90 and a beta of 0.59. The company has a 50-day moving average of C$0.07 and a 200 day moving average of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
See Also
- Five stocks we like better than Hemostemix
- The SpaceX IPO Frenzy Is Creating 2 Very Different Bets
- AI Can’t Reach the Real World Without These 3 Stocks
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
